

VolitionRx

09:56 29 Oct 2019

VolitionRx gets \$500,000 loan to continue build-up of veterinary medicine subsidiary

VolitionRx Limited (NYSEAMERICAN:VNRX) has received a \$500,000 loan to further the development of its Volition Veterinary Diagnostics Development LLC subsidiary.

Specifically, the new infusion of non-dilutive funding comes from SOFINEX, a funding agency of the Walloon Region, where Volition is based.

READ: VolitionRx's veterinary subsidiary wins 12.5% equity stake from Texas A&M

"We are delighted with the non-dilutive financial support we continue to receive as it allows us to develop Nu.Q Vet products in the very exciting veterinary market," Gaetan Michel, CEO of Belgian Volition. "We would like to thank SOFINEX for this latest loan which takes our non-dilutive funding total from local agencies and the Walloon government to over \$6 million to-date."

On October 25, Volition signed multiple agreements with Texas A&M University to help develop its Nu.Q Vet products, and the institution now holds a 12.5% stake in the company. The two parties recently attended a signing ceremony at the school's College of Veterinary Medicine & Biomedical Sciences.

Volition's Nu.Q platform looks for molecular signatures of cancer by focusing on the nucleosomes - a section of DNA wrapped around a core of proteins - in the blood. As cancer cells multiply, they are modified in a way that distinguishes them from healthy cells and the traits of the malignant disease appear on the nucleosomes, which are analyzed by the platform.

The company and the university together have been studying a version of its blood-based tests for animals called Nu.Q Vet after discovering that nucleosomes in the blood can also be detected in dogs.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a

Price: 4.74

Market Cap: \$194.78 m

1 Year Share Price Graph



Share Information

Code: VNRX

Listing: NYSEMKT

52 week High Low
6.83 2.11

Sector: Pharma & Biotech

Website: volitionrx.com

Company Synopsis:

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present.

action@proactiveinvestors.com

security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).